Medela Receives Innovative Technology Contract from Vizient for Invia® Liberty™ and Invia Motion® NPWT Systems

MCHENRY, Ill., March 13, 2020 /PRNewswire/ — Medela LLC, announced its Invia Liberty and Invia Motion Systems have received an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the country. The contract was based on the recommendation of Invia Liberty and Invia Motion negative pressure wound therapy systems (NPWT) by hospital experts in this category who serve on one of Vizient’s member-led councils.

“For Medela to be recognized by the experts and receive the Innovative Technology contract is exceptional,” said Melissa Gonzales, executive vice president of the Americas for Medela LLC. “Healthcare is a dynamic marketplace and we look forward to working with the full Vizient membership group through this contract to help their member hospitals enhance clinical and patient care with important medical vacuum technology.”

“After a review of Invia Liberty and Invia Motion NPWT Systems, Vizient’s member council agreed this technology offers a unique benefit over other products available in the market today and recommended it for an innovative technology contract. We are pleased to award this new contract to Medela,” said Debbie Archer, director of procurement and leader of the Vizient Innovative Technology program for suppliers.

The Invia Liberty and Invia Motion NPWT systems deliver prescribed pressure at the dressing site (Intelligent Pressure Control) and actively help prevent blockages with airflow cycles adapting up to four times a minute depending on the level of volume and viscosity (Dynamic Exudate Removal). Medela’s systems follow the international recommendations for NPWT set by the European Wound Management Association (EWMA) and offer an electronically controlled feedback system to maintain the therapy prescribed by the physician.

Vizient represents a diverse membership base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks, and non-acute health care providers and represents approximately $100 billion in annual purchasing volume.

Through its Innovative Technology Program, Vizient works with member-led councils and task forces to review potentially innovative products. If it is determined that a product is innovative, Vizient may award a contract outside of the competitive bid cycle.

To learn more about Medela’s complete negative wound pressure therapy system, visit Medela.com. To request information about how to purchase, fill out our online form to connect with a Medela sales consultant.

Photo(s):
https://www.prlog.org/12814415

Press release distributed by PRLog

View original content:http://www.prnewswire.com/news-releases/medela-receives-innovative-technology-contract-from-vizient-for-invia-liberty-and-invia-motion-npwt-systems-301023213.html

SOURCE Medela LLC

Staff

Recent Posts

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…

4 hours ago

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…

7 hours ago

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…

7 hours ago

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…

7 hours ago

Best Peptides for Anti-Aging: NAD+ Delivery Methods Compared as Telehealth Platforms Expand Access (2026 Analysis)

Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…

7 hours ago

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…

7 hours ago